Evaluating Landmark Clinical Data for HER2-low Breast Cancer

Host: Pavani Chalasani, MD, MPH Guest: Prof. David Cameron A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.